Andrea Dunlap, PA
Physician Assistant · Elizabeth City, NCNPI 1073554663
Payments from drug & device makers
Across 1,110 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- Johnson & Johnson$1K
- USWM, LLC$1K
- Otsuka America Pharmaceutical, Inc.$1K
- plus $9K from 25 others
What the payments were for
- Food & beverage$17,57092%
- Education$4332%
- Gifts$1,0135%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 175 | $2,333 |
| Teva Pharmaceuticals USA, Inc. | 113 | $2,146 |
| Neurocrine Biosciences, Inc. | 136 | $1,762 |
| Johnson & Johnson | 68 | $1,425 |
| USWM, LLC | 15 | $1,225 |
| Otsuka America Pharmaceutical, Inc. | 69 | $1,063 |
| Alkermes, Inc. | 47 | $1,024 |
| Indivior Inc. | 50 | $918 |
| Supernus Pharmaceuticals, Inc. | 41 | $917 |
| Vanda Pharmaceuticals Inc. | 34 | $812 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 42 | $803 |
| Lundbeck LLC | 48 | $706 |
| Takeda Pharmaceuticals U.S.A., Inc. | 47 | $573 |
| Almatica Pharma LLC | 54 | $552 |
| Corium, LLC | 33 | $422 |
| Merck | 23 | $410 |
| Bausch Health US, LLC | 21 | $372 |
| Avanir Pharmaceuticals, Inc. | 19 | $305 |
| Idorsia Pharmaceuticals US Inc | 16 | $235 |
| Sunovion Pharmaceuticals Inc. | 18 | $222 |
| Eisai Inc. | 10 | $152 |
| Tris Pharma Inc | 7 | $136 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $126 |
| Ironshore Pharmaceuticals Inc. | 5 | $101 |
| E.r. Squibb & Sons, L.L.C. | 4 | $93 |
| Adlon Therapeutics L.p. | 3 | $45 |
| Collegium Pharmaceutical, Inc. | 2 | $35 |
| Noven Pharmaceuticals, Inc. | 1 | $33 |
| Noven Therapeutics, LLC | 2 | $32 |
| Pear Therapeutics (US), Inc. | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZIMHI$1,013
How this compares
$19,016 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 55 | $462,518 |
| AustedoDeutetrabenazine | 43 | $250,656 |
| VraylarCariprazine Hcl | 119 | $172,749 |
| Invega TrinzaPaliperidone Palmitate | 17 | $163,864 |
| RexultiBrexpiprazole | 100 | $148,035 |
| FanaptIloperidone | 33 | $90,804 |
| TrintellixVortioxetine Hydrobromide | 110 | $60,610 |
| Invega SustennaPaliperidone Palmitate | 13 | $45,730 |
| LybalviOlanzapine/Samidorphan Malate | 21 | $39,036 |
| Lurasidone Hcl | 139 | $24,613 |
| QuviviqDaridorexant Hcl | 45 | $23,886 |
| BelsomraSuvorexant | 51 | $23,481 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 108 | $22,975 |
| AuvelityDextromethorphan Hbr/Bupropion | 15 | $17,904 |
| Aripiprazole | 188 | $12,964 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,762 | $462,51855 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Loxapine | $2,146 | $252,53054 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $1,425 | $209,59430 claims |
| AbbVieVraylar | $2,333 | $172,749119 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,063 | $148,035100 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $812 | $90,80433 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $573 | $60,610110 claims |
| Alkermes, Inc.Lybalvi | $1,024 | $39,03621 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $235 | $23,88645 claims |
| MerckBelsomra | $410 | $23,48151 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $17 | $22,975108 claims |
| Eisai Inc.Dayvigo | $152 | $9,64222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.
Other physician assistant in Elizabeth City
- Jo HughesGreensboro$814K
- Rachel HolzhauerCharlotte$739K
- Amber BlairCharlotte$551K
- Benjamin EpsteinDavidson$447K
- Rebecca KrausDavidson$425K
- Brooke JonesGoldsboro$259K
- Philip ReasbeckWilson$180K
- Katherine SchultzHuntersville$164K
- Kristin CabedaCharlotte$135K
- Jay ClarkeArden$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.